Compare Amylx Pharmaceuticals Inc (AMLX) vs Booking Holdings Inc (BKNG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Booking Holdings Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Booking Holdings Inc trades at $178.79 (market cap $138.23B). The key difference: Booking Holdings Inc is far larger — about 69.8× Amylx Pharmaceuticals Inc's market cap, and Booking Holdings Inc pays a 0.9% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | BKNG | |
|---|---|---|
Market Cap | $1.98B | $138.23B |
Sector | Health | Consumer Cyclical |
52-Week High | $18.70 | $231.02 |
52-Week Low | $7.64 | $154.13 |
Enterprise Value | $1.70B | $141.15B |
Dividend Yield | — | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Booking Holdings (BKNG) trades at $178.39, up 1.64% with mixed technical signals showing bearish overall momentum but bullish moving averages. The company maintains strong fundamentals with $26.92B revenue and 22.23% net margin in 2025, though Q2 2026 earnings remain pending. Recent news highlights AI integration efforts and travel demand resilience despite geopolitical concerns.
BKNG presents a compelling valuation case with analyst consensus target of $222.81 (25% upside) and no sell ratings. Key risks include AI disruption fears and Middle East tensions, but the company's dominant OTA position and robust cash flow generation support long-term growth prospects in the travel recovery cycle.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Booking Holdings Inc
Booking is the world's largest online travel agency by revenue, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates a number of branded travel booking sites, including Booking.com, Agoda, OpenTable, and Rentalcars.com, and has expanded into travel media with the acquisitions of Kayak and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.
Read more on BKNG →
